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Objective: Between January 1993 and May 1998, we performed 200 consecutive bilat-
eral lung volume reduction operations. After initial assessment, 99 of these patients
were eligible for lung volume reduction and potentially eligible for immediate or even-
tual lung transplantation on the basis of age and absence of contraindications. All chose
to proceed with lung volume reduction surgery. The outcomes of these 99 patients are
reviewed to assess the consequences of proceeding with lung volume reduction surgery
on patients potentially eligible for lung transplantation.
Methods: A retrospective study was performed with the use of a prospectively
assembled computer database.
Results: The 61 men and 38 women were 55 ± 7 years old at evaluation for lung
volume reduction. Mean values for first second expired volume, total lung capaci-
ty, and residual volume were 24% ± 8%, 141% ± 19%, and 294% ± 54% predict-
ed. There were 4 operative deaths and 17 late deaths. Two-year and 5-year survival
after evaluation for lung volume reduction are 92% and 75%. The 32 patients who
have been listed for transplantation after lung volume reduction include 15 who
have undergone transplantation, 14 who remain on the list, and 3 who have been
removed from the list. All 15 transplant recipients survived transplantation and 3
have subsequently died of rejection or late infection. The 12 living recipients have
a median post-transplantation follow-up of 1.7 years. The age at transplantation was
58 ± 5 years with transplantation occurring 3.8 ± 1.1 years after lung volume reduc-
tion. Sixteen of 99 patients underwent lower lobe volume reduction with an
increased rate of listing (63%, P = .008) and transplantation (38%, P = .003) com-
pared with patients undergoing upper lobe volume reduction. Patients listed for
transplantation were younger, more impaired, and experienced less benefit from
lung volume reduction than patients not yet listed for transplantation.
Conclusions: The preliminary use of lung volume reduction in patients potentially
suitable for transplantation does not appear to jeopardize the chances for subsequent
successful transplantation. 
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Otto Brantigan initially proposed the con-cept of lung volume reduction surgery(LVRS) for emphysema by suggesting thatresection of functionless, overinflatedlung tissue might improve respiratoryfunction.1,2 Several years ago, we reported
our preliminary experience with bilateral LVRS.3
Subsequent encouraging results from many centers have
demonstrated significant improvements in pulmonary func-
tion tests and exercise tolerance along with reduction in
oxygen use, reduction in subjective dyspnea, and improve-
ment in subjective health status.4-6
We began performing LVRS in January 1993 and per-
formed 225 bilateral operations over the next 6 years. The
clinical results of this operation have been described.4 One
of the initial driving forces to establish LVRS arose from
the observation that many patients with severe emphysema
who were referred for lung transplantation would never be
eligible for transplantation. This ineligibility resulting from
age or comorbidities identified a population of patients
from which many of our earliest LVRS patients were
drawn. As the efficacy and safety of LVRS became better
established, it became apparent that LVRS might reason-
ably be applied to patients still under consideration for
transplantation. Previously we offered lung transplantation
only to patients with no other treatment option. However,
the positive results after LVRS in patients ineligible for
transplantation effectively created another surgical option
for some transplant candidates: LVRS as a first step with
potential for a lung transplantation at a later date. In some
cases this LVRS may serve as a bridge to transplantation
when a patient’s life expectancy appears less that the antic-
ipated waiting time for a lung transplant.
Our institutional bias has been that the best candidates
for LVRS and the best candidates for lung transplantation
constitute distinct groups with little overlap.7 However,
because the natural history of emphysema with or without
LVRS is one of progressive deterioration, we have frequent-
ly applied LVRS to individual patients with the expectation
that many might later seek transplantation. It is these
patients who make up the substance of this report. We
sought to look retrospectively at the results of LVRS in a
population of patients who were free of contraindications
for transplantation at the time of the LVRS operation and
who thus might become transplant candidates in the future.
Methods
Patient Population
We retrospectively searched our database to identify patients who
had undergone bilateral LVRS who were, or could have been, con-
sidered candidates for transplantation at the time of LVRS. In gen-
eral, patients with severe chronic obstructive pulmonary disease
were selected for LVRS on the basis of the presence of a distend-
ed thorax and significant functional limitation despite standard
medical therapy. Patients who underwent LVRS for giant emphy-
sematous bullae, in the presence of nearly normal underlying com-
pressed lung, were excluded from this report. Patients who contin-
ued to smoke were excluded from consideration. The details of the
evaluation process have been fully described.8
The term transplant eligibility is an artificial classification that
was retrospectively applied for the purposes of this report. To be
considered transplant eligible, patients had to be less than 65 years
of age and free of contraindications to lung transplantation. Figure
1 is a frequency histogram showing the age distributions of the 99
patients in this study, as well as the 267 patients with emphysema
who have undergone lung transplantation in our program since
1988. The rarity of patients over the age of 65 years receiving
transplantation in our program is justification of the use of this age
as a cutoff for inclusion in this retrospective study. We placed no
specific upper limit on lung function as part of this classification
because the progressive nature of emphysema leads to eventual
deterioration of pulmonary function in all of these patients. In
keeping with our overall selection process for LVRS, the mean
forced expiratory volume in 1 second (FEV1) in this group of
patients was 690 ± 240 mL, a value that is less than 25% predict-
ed and represents substantial impairment. 
Assessment
Physiologic assessment included standard pulmonary function
studies, plethysmographic measurement of lung volumes, stan-
dardized 6-minute walk test, arterial blood gas values, quantitative
nuclear lung perfusion scans, and a radionuclide cardiac ventricu-
logram.
Anatomic assessment included posteroanterior and lateral chest
x-ray films taken in inspiration and expiration, chest computed
tomographic scan, and, in some patients, dynamic magnetic reso-
nance imaging evaluation of chest wall and diaphragmatic move-
ment and coordination. If pulmonary hypertension was suspected
on the basis of the clinical examination or the right ventriculogram
results, a right heart catheterization was performed. If significant
coronary artery disease was suspected, catheterization of the left
side of the heart was also done.
Timing of the Operation
After evaluation, virtually all patients were enrolled in a structured,
supervised exercise rehabilitation program for a minimum of 6
weeks. In addition to the required 6-week rehabilitation delay
between evaluation and surgery, additional delays were introduced
on an individual patient basis to address issues raised at the time of
evaluation. The interval between evaluation and LVRS in these
patients ranged from 29 to 555 days with a median preparation
time of 97 days.
Technique of Operation
The techniques used for the operation performed have previously
been described.4 A thoracic epidural catheter was placed immedi-
ately before the operation, thereby eliminating the need for intra-
operative systemic narcotic agents. A left-sided double-lumen
endotracheal tube was used. The anesthetic management of these
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patients has been previously described.9 A standard median ster-
notomy incision was made and the mediastinal pleura was incised
several centimeters posterior to the sternum to facilitate subse-
quent closure of the pleura at the end of the procedure. Care was
taken to avoid incising the pleura too far cephalad to avoid injury
to the phrenic nerve. One lung was deflated while ventilation was
directed to the contralateral side. Under these conditions, after a
few minutes, the relatively healthy portions of lung undergo
absorptive atelectasis whereas the most destroyed portions remain
inflated because of the poor or absent pulmonary blood flow. In
some instances, when the lobe in question was uniformly
destroyed by emphysema, an anatomic lobectomy was performed
in lieu of a stapled volume reduction.
A linear stapler was used to excise the selected diseased areas
of lung. The staplers were buttressed with strips of bovine peri-
cardium (Peri-Strips, Bio-Vascular, Inc, St Paul, Minn) using a
technique previously reported.10 Two 28F chest drains are placed
in each pleural space and brought out in the subxiphoid position at
the conclusion of the operation. Postoperative care has also been
discussed in detail elsewhere.4
Follow-up Evaluation
Follow-up evaluation of all patients in both groups included tele-
phone interviews and office visits to assess general health, func-
tional status, and dyspnea. Overall patient satisfaction was
queried by asking the following question: “On the basis of how
you feel now, how would you rate the outcome of your volume
reduction operation?” Patients were asked to choose from the fol-
lowing responses: 5 = excellent, 4 = very good, 3 = good, 2 = fair,
1 = poor. These interviews included questions regarding use of
supplemental oxygen at rest and during exercise, as well as
steroid use. We asked patients to return every 6 months for fol-
low-up spirometry and lung volume measurements. Data describ-
ing survival, transplant listing, and actual transplantation are cur-
rent as of March 2000 and functional data are complete as of
November 1999. 
Statistical Analysis
The mean and standard deviation were used to describe continuous
data. Patient counts and percentages were used to describe cate-
gorical data. The 2-tailed Wilcoxon rank sum test was used to com-
pare continuous data between groups. The Fisher exact test was
used to compare categorical data between groups. Kaplan-Meier
plots were used to graphically display survival, freedom from list-
ing for transplantation, and freedom from transplantation, with the
starting point for both groups being the day of evaluation for
LVRS. The Mantel-Haenszel log rank statistic was used to deter-
mine the significance of survival differences.
Results
Between January 1993 and May 1998, we performed 200
consecutive bilateral LVRSs for patients with emphysema.
Ninety-nine of these patients were considered potentially
eligible for lung transplantation on the basis of age and
absence of contraindications. The patients included 61 men
and 38 women with an age of 55 ± 7 years. The FEV1 was
24% ± 8% predicted, the residual volume was 294% ± 54%
predicted, the total lung capacity was 141% ± 19% predict-
ed, and the diffusion capacity for carbon monoxide was
34% ± 17% predicted. The current status reflects a median
follow-up of 5.1 years from evaluation with a range of fol-
low-up from 2.2 to 7.1 years. The shortest follow-up from
the actual LVRS is 1.9 years.
Ninety patients underwent the standard bilateral stapled
volume reduction via a median sternotomy. In 74 patients the
resection was for upper lobe predominant destruction, and in
16 the lower lobes were the site of resection. Nine of the 99
patients underwent a total of 11 anatomic lobectomies in the
process of undergoing bilateral lung reduction. These opera-
tions included 6 right upper lobectomies, 1 left upper lobecto-
my, 2 right middle lobectomies, and 2 left lower lobectomies. 
Figure 1. Frequency histogram showing age distribution of patients undergoing LVRS and lung transplantation
(TXP). The LVRS group includes the 99 patients described in the current report. The lung transplantation group
includes all patients with a diagnosis of emphysema who have undergone transplantation in the Washington
University program since 1988.
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Four postoperative deaths occurred either in the initial
hospitalization or within 30 days after LVRS. The overall
survival of the 99 patients is depicted in Figure 2. The func-
tional outcome is described by the changes in pulmonary
function in the 80 patients with 6-month follow-up data. The
FEV1 improved from 24% ± 8% predicted at evaluation to
38% ± 14% at 6 months’ follow-up, an improvement of 56%
from baseline. The residual volume decreased from 294% ±
54% to 201% ± 55% for a decrease of 32% of baseline. The
6- to 12-month overall patient satisfaction scores in the
entire group show that most patients were quite satisfied
with the outcome of surgery. There were 77 responses with
a mean response of 4.4 and a median value of 5 on the pre-
viously described scale of 1 to 5 (poor to excellent).
To date, 32 patients have been listed for lung transplan-
tation after receiving bilateral LVRS. Of the 32 listed
patients, 15 have undergone transplantation, 14 remain on
the waiting list, and 3 have been removed from the waiting
list as a result of death or other reasons. Eight of the 14
patients are described as “active” on the waiting list, and 6
are considered “inactive” because they have accrued sub-
stantial time on the list but their lung function is considered
to be too good to warrant transplantation at this time. Figure
3 is a Kaplan-Meier curve depicting freedom from trans-
plant listing as a function of time since evaluation for LVRS.
By 5 years from the time of LVRS, 40% of the survivors
have been listed for transplantation. Table 1 compares the
unlisted, listed, and transplanted patients according to
selected demographic and baseline physiologic criteria.
Listed patients are younger and have lower FEV1 scores at
the time of evaluation than unlisted patients. Other physio-
logic parameters at the time of evaluation are not signifi-
cantly different when the listed and unlisted cohorts are
compared.
The 15 patients who have undergone transplantation
ranged in age from 48 to 64 years at the time of transplan-
tation. The mean age was 57.5 ± 5.1 years. The mean time
from LVRS to transplantation was 3.8 ± 1.1 years, with a
range of 2.1 to 6.0 years. At the time of evaluation these
patients were 53.9 ± 4.6 years with a range of 45 to 62 years
of age. With the exception of the oldest patient in the group,
no patient older than 58 years at the time of evaluation has
undergone transplantation after LVRS. The initial improve-
ment caused by LVRS in patients who subsequently went on
to transplantation was comparable in many respects to the
initial response experienced by patients not listed for trans-
plantation. The increase in FEV1 at 6 months in these 15
patients was 47% ± 35% over baseline, and the 6- to 12-
month patient satisfaction scores after LVRS were a mean of
3.8 and a median of 4 based on 13 responses. The 15 trans-
plant recipients were re-evaluated just before transplanta-
tion, and the results were compared with physiologic
indices obtained at the time of LVRS evaluation nearly 4
years previously. The fraction of these 15 patients requiring
continuous use of supplemental oxygen at rest decreased
from 62% to 23% between evaluation for LVRS and evalu-
ation immediately before transplantation. The mean dis-
tance traveled in a 6-minute walk was 933 feet at LVRS
evaluation and 1141 feet just before transplantation. The
Medical Research Council dyspnea index improved from
3.2 at evaluation for LVRS to 2.9 before transplantation.
The fraction of patients using supplemental oxygen at exer-
cise increased from 92% to 100%. All 15 patients survived
transplantation. Three have subsequently died, and each
death occurred more than 1 year after transplantation. The
remaining 12 recipients are still alive with a median survival
of 1.7 years (range 0.2-3.3 years)
Figure 3 shows the overall Kaplan-Meier freedom from
transplantation and Figure 4 shows freedom from listing for
transplantation stratified according to 4 levels of preoperative
FEV1. When patients are stratified by FEV1, the differences
in transplantation risk are not statistically significant 
Figure 2. Kaplan-Meier curve showing survival of 99 potentially
transplant-eligible patients after bilateral LVRS.
Figure 3. Kaplan-Meier curve showing freedom from transplanta-
tion and freedom from listing for transplantation of 99 potentially
transplant-eligible patients after bilateral LVRS.
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(P = .18). Although only 1 transplant operation has been per-
formed in a patient older than 60 years at evaluation, the dif-
ference in the transplant risks of the older and younger strata
lacks statistical significance by the log rank test (P = .09). The
difference in the rate of progression to transplantation in the
patients treated with lower lobe volume reduction as com-
pared with upper lobe volume reduction is statistically signif-
icant by the log rank test (P = .003), as shown in Figure 5.
We have previously noted that the improvement in
FEV1 after lower lobe LVRS is less than that seen after
upper lobe LVRS despite the fact that the reduction in
residual volume is similar. We have presumed that the
physical properties of the remaining lung differ between
these two types of emphysema, resulting in a less durable
long-term result in patients with lower lobe predominant
emphysema. The 16 patients receiving lower lobe bilateral
LVRS were not significantly younger than patients having
upper lobe LVRS (53 ± 7 years vs 55 ± 6 years; P = 0.27),
nor were they significantly more impaired at the time of
evaluation (FEV1 24% ± 6% vs 24% ± 7%). The lower
lobe patients had a poorer objective response to bilateral
LVRS, with an improvement in FEV1 measured at 6
months of 30% ± 33% versus 63% ± 45% for the upper
lobe patients. As a consequence of this poorer result from
bilateral LVRS, 10 (63%) of the 16 lower lobe patients
have been listed for transplantation as compared with 22
(27%) of the 83 upper lobe patients, a difference that is
statistically significant (P = .008).
We investigated α1-antitrypsin deficiency as an indepen-
dent risk for transplantation after LVRS. Ten of the 99
patients have been conclusively identified as having α1-
antitrypsin deficiency. Because we did not routinely test
patients with predominantly upper lobe disease for α1-anti-
trypsin deficiency, the overall prevalence of the condition
within these 99 patients is not known. Six of the patients in
whom this disorder was confirmed have undergone trans-
plantation. Two of the remaining patients died without ever
being listed (rectal abscess in 1 patient; Aspergillus, pul-
monary embolus, and breast carcinoma in the other) and 2
patients are currently 64 and 65 years old and are not listed.
Because patients with α1-antitrypsin deficiency frequently
present with primary lower lobe destruction, and because of
the poor results we observed after lower lobe LVRS, these
patients are now preferentially referred for transplantation. 
Twenty-three patients are currently alive, are unlisted for
transplantation, and are considered too old to be listed. At
the time of evaluation they were 61 ± 2.0 years old (range
57-64 years). These patients have now survived 4.3 ± 1.2
years after LVRS with a range of 1.4 to 6.3 years. At the
time of evaluation, the FEV1 for this group was 24% ± 5%,
the residual volume was 300% ± 49%, and the total lung
capacity was 147% ± 20%. The initial response of this
group of patients to LVRS as measured by 6 months’
improvement in FEV1 was 66% ± 28%. The subjective
patient satisfaction score in these patients 6 to 12 months
after LVRS was a mean of 4.5 and a median of 5, with 18 of
the 23 patients responding.
Discussion
The role of LVRS in patients who are eligible for transplan-
tation continues to be defined. The decision is often difficult
and requires a good deal of discussion with the patient and
family. One particularly vexing issue is the relative value of
an acceptable quality of life compared with length of life.
For example, some evidence suggests that lung transplanta-
tion is a palliative operation that may actually shorten the
life expectancy of the recipient with emphysema in
exchange for relief of dyspnea and disability.11 This deter-
mination takes into consideration the stable survival trend
observed in patients with chronic obstructive pulmonary
disease on the lung transplant waiting list and the current 5-
year survival estimates of 40% to 50% after transplantation.
TABLE 1. Characteristics of patients listed for transplantation versus all patients not listed for transplantation
Characteristic Not listed for transplantation (n = 67) Listed for transplantation (n = 32) P values, listed vs not listed
Male/female 50/17 11/21 <.001
Age at evaluation (y) 56 ± 7 53 ± 6 .01
FEV1% evaluation 25 ± 7 22 ± 6 .02
RV% at evaluation 288 ± 56 307 ± 49 .09
TLC% at evaluation 141 ± 20 142 ± 17 .99
DLCO% at evaluation 36 ± 17 32 ± 15 .10
6 mo ∆ FEV1% 65 ± 45 44 ± 41 .04
Lower lobe LVRS 6 10 .008
Upper lobe LVRS 61 22
Patient satisfaction score at 6 mo 4.6 ± 0.7 (n = 45) 4.2 ± 0.8 (n = 17) .13
FEV1%, First second forced expiratory volume expressed as a percent of predicted; RV%, residual volume expressed as a percent of predicted; TLC%, total
lung capacity expressed as a percent of predicted; DLCO%, diffusion capacity for carbon monoxide expressed as a percent of predicted; 6 mo ∆ FEV1%,
the improvement in the FEV1% expressed as a percentage of the value measured at evaluation. Patient satisfaction scores were recorded as whole num-
bers (1-5) with 5 being the best and 1 being the worst.
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On the other hand, most lung transplant recipients report a
dramatic enhancement in the quality of life that may persist
in a minority of patients for 10 years or more. By contrast,
evidence to date suggests that both quality of life and
longevity are improved with LVRS compared with nonsur-
gical treatment. We have previously published results in a
group of Medicare patients who, having been selected for
LVRS, were subsequently denied the operation because of
the Medicare funding withdrawal in 1996. These patients
were compared with an identical group of Medicare patients
who received the operation in the year before the withdraw-
al of funding.12 At the time of our initial publication there
was a trend toward improved survival in the surgical group,
which has now reached statistical significance.13 Patients
denied the operation had a median survival of 3.4 years
whereas the median survival has not yet been reached at
almost 5 years in the Medicare patients who received the
operation. The National Emphysema Treatment Trial is cur-
rently attempting to prospectively address the impact of
LVRS on survival in a multicenter trial.
Almost uniformly, patients with severe chronic obstruc-
tive pulmonary disease choose a surgical option (LVRS or
transplantation) and its attendant risks over continued med-
ical therapy, thereby assigning more importance to the qual-
ity of life than to longevity. Issues of quality and length of
life notwithstanding, the surgical strategy for a “dual” LVRS
and lung transplant candidate remains complex. The greater
improvement in lung function offered by transplantation
must be balanced against the lifelong need for immunosup-
pression and the continued risk for infection and chronic
rejection. The waiting time for LVRS depends only on the
length of preoperative rehabilitation, whereas the current
waiting time for transplant recipients is 700 days in our pro-
gram. If past trends hold, it is likely that patients listed today
will routinely wait more than 2 years for suitable donor
lungs. Finally, although no formal policy on age has been
formulated, it is unlikely that a patient older than 65 years
will be listed for transplantation. 
What can we advise a 55-year-old dual candidate about
his or her likelihood of becoming a transplant recipient?
What will be the impact of preliminary LVRS on the
chances of obtaining a transplant and the success of a trans-
plant if it is obtained? It is in this context that our results can
provide guidance. 
To analyze the impact of a particular surgical interven-
tion, such as LVRS or transplantation, one can use the clas-
sic Kaplan-Meier method of describing freedom from
“events” over a period of time from a starting point that is
common to all subjects. Freedom from death, when mea-
sured as a function of time since evaluation or time since
LVRS, is a reasonable measure of the effectiveness of the
LVRS and of the judgment used to select surgical therapy
for emphysema. Other events that can be used to chart the
outcome for patients undergoing LVRS are the decision to
list a patient for transplantation and the event of transplan-
tation itself. With regard to listing and transplanting, both
events can be viewed simultaneously as successes and fail-
ures of the initial therapy. The failure is clearly evident: an
operation designed to improve symptoms of dyspnea has
certainly lost its continuing benefit when the recipient of
that operation undergoes lung transplantation. In young
patients, however, this can be seen as a success. If the choic-
es for a patient were previously limited to transplantation or
medical therapy, and if the transplant had an 5% to 8% mor-
tality and a 50% 5-year survival, then a procedure such as
LVRS that could palliate dyspnea, improve exercise capa-
bilities, and delay entry onto the steeper post-transplantation
survival curve would be most beneficial if it resulted in a
transplant in every case. In that light, the critical measure
would be time to failure as determined by time until trans-
plantation or time until the patient’s condition deteriorated
to a functional and symptomatic level worse than that expe-
rienced before the procedure.
Figure 4. Kaplan-Meier curve showing freedom from listing for
transplantation of 99 potentially transplant-eligible patients after
bilateral LVRS stratified by FEV1 at the time of evaluation. Figure 5. Kaplan-Meier curve showing freedom from transplanta-
tion in 99 patients undergoing bilateral LVRS stratified by site of
LVRS: upper lobe versus lower lobe. 
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Therefore, we must conclude that the goal of LVRS in
these patients should be to provide relief from dyspnea, to
produce an improved functional status, and to get the patient
in optimal physical condition for subsequent transplanta-
tion. Eventual transplantation is expected, or even desired,
but the role of LVRS is to palliate symptoms during the pro-
longed waiting period and to delay, as long as possible, the
entry onto the steeper survival curve seen after lung trans-
plantation. The question of what degree of palliation for
what length of time is sufficient to merit the risks of LVRS
is a value judgment. In our 15 patients who underwent trans-
plantation, the time from LVRS to transplantation varied
from 2.1 to 5.9 years. Although a longer latency from LVRS
to transplantation is better, even the shortest palliation may
be worthwhile if it enhances survival and quality of life and
results in improved fitness and endurance at the time of
actual transplantation. 
Patients for whom successful LVRS may pose a dilemma
comprise a subgroup worthy of additional scrutiny. An exam-
ple would be a patient who, at the age of 61 years, would be
considered a good candidate for either lung transplantation or
LVRS. A successful LVRS would likely provide 3 to 5 years
of palliation from the dyspnea that led to treatment in the first
place, but when the progression of the emphysema reversed
the results of surgery, such a patient would be viewed by
many transplant programs as too old to list. Such a circum-
stance is likely to be rare, but the theoretical problem it rep-
resents is worthy of comment. One corrective measure would
be to list the patient earlier than symptoms might otherwise
dictate, but that runs into the moral dilemma caused by an
overall shortage of donor lungs and the excessively high rate
of death of sicker patients on the waiting list who are in more
dire need of transplantation. At the time of this writing,
almost half of the listed patients in this described experience
who are alive and have not yet undergone transplantation
(6/14) are inactive on the waiting list. This status change has
occurred because the patients were nearing the top of the
waiting list in too good a condition to merit the risks of trans-
plantation. This phenomenon suggests that we still have much
to learn about the optimal timing of listing patients with
emphysema for transplantation.
In conclusion, LVRS appears to be a reasonable strategy
in highly selected patients eligible for LVRS and potential-
ly eligible for transplantation at the time of evaluation. The
outcome from LVRS in patients potentially eligible for
transplantation appears comparable with that seen in all
patients treated with LVRS. A minority of such patients will
actually go on to transplantation, and the mean interval from
LVRS to transplantation will be nearly 4 years. Patients
undergoing transplantation are younger at the time of eval-
uation than patients not proceeding to transplantation. The
initial improvement in lung function does not appear to dis-
criminate between patients likely or unlikely to proceed to
transplantation. Patients in whom lower lobe destruction is
predominant appear more likely to require subsequent trans-
plantation. In our experience with 15 patients to date, there
has been no increased mortality in patients subjected to lung
transplantation after prior LVRS.
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Discussion
Dr Douglas E. Wood (Seattle, Wash). I congratulate Dr Meyers
and his colleagues at Washington University for yet another impor-
tant analysis of their large experience in the surgical treatment of
end-stage lung disease. The Washington University group have
been consistent leaders in the development and evaluation of both
LVRS and lung transplantation. They have also consistently
obtained enviable results in both procedures and are in a position
to show the best that can be expected in LVRS, lung transplanta-
tion, and in this case, LVRS in lung transplant candidates. 
A quick overview of the results in this paper would seem to show
that the glass is half empty or half full, depending on your perspec-
tive. Among 99 patients undergoing LVRS, there was a 4% early and
17% late mortality, with 32% of patients subsequently listed for lung
transplantation. From one perspective, it would appear that LVRS
failed in 53% of patients, because they either died or required trans-
plantation. From yet another perspective, nearly 50% of patients who
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Dr Meyers (St Louis, Mo). Thanks for all those comments. 
Dr Wood, you mentioned failure, a word that we avoid when we
discuss transplantation after LVRS. We view the consequent progres-
sion of the emphysema leading to transplantation as a predictable nat-
ural extension of the patient’s pre-LVRS emphysema. Particularly
with respect to the late transplantations or listings, they certainly
should not be viewed as the consequence of failure of LVRS. 
The harder part of your question was to set up an algorithm to
offer optimal surgical therapy to these patients. Once one has made
the leap and decided that a patient is actually truly eligible for both
procedures, I think the dilemma is to involve the patient as much
as possible in the decision-making process. The patients are the
ones that will be exposed to the higher risk or the lower benefit,
depending on how they decide. If you looked at unilateral LVRS,
bilateral LVRS, and transplantation as surgical therapies with
increasing benefit available to the patient, yet increasing risk to
which they would be exposed, I believe each patient’s personality
would dictate how much morbidity and mortality should be risked
for increased functional gain. 
With regard to the age of the patient, of the multiple factors that
we evaluated, several are true risks factors, whereas younger age is
more of a permissive factor with regard to transplantation. We
could not demonstrate a statistically significant difference with a
cutoff at age 60 years, but I would say that only 1 patient who was
60 years or older at the time of LVRS subsequently went on to
transplantation. That patient had the transplant operation at anoth-
er center and likely would not have been offered transplantation at
our center. Therefore, the algorithm is very difficult and by neces-
sity involves careful consultation with the patient according to his
or her comfort with the risks. 
Dr Egan mentioned the difficulty of the pneumonectomies, and
I would echo that. We have performed transplantation in a lot of
patients who probably have chimeric lungs, with the cortex being
the residual volume–reduced native lung and the medulla being the
newly transplanted lung. In many cases we leave the visceral pleu-
ra and some lung tissue behind in the hopes of avoiding injury to
the recurrent laryngeal nerve and the phrenic nerve. 
I do not have information regarding the single and double lung
question. I can tell you that 8 of the 15 transplants were performed
by us at Washington University, and we definitely have a propen-
sity toward bilateral transplantation. The other 7 were performed at
other centers, and I would estimate that they were probably split
evenly between bilateral and single lung transplantations. 
Dr Swanson mentioned the hazards of dealing with phrenic
nerves. Peri-Strips tend to have a magnetic attraction toward nerve
tissue, particularly after 3 or 4 years of opportunity to migrate
there. On many occasions we have just left the Peri-Strips and the
attached lung stuck to the mediastinum in hopes of avoiding the
nerves and the subsequent diaphragmatic injury. I cannot provide
numbers, though, on the prevalence of phrenic or recurrent nerve
injury resulting from these dissections. 
Dr Yang inquired about LVRS after lung transplantation. To my
recollection, we have only attempted that one time in a woman
who had a very severe bronchiolitis obliterans after a single lung
transplantation, and it proved not to be beneficial for her. The
majority of our patients are receiving bilateral transplants, and so
volume-reducing the native side is not a decision we are faced with
very frequently. 
were candidates for lung transplantation have been able to delay or
avoid transplantation. With the current shortage of organs, this may
be a valuable outcome for these patients. 
The goals of LVRS in transplant-eligible patients are 3-fold—
to avoid or delay transplantation or to improve quality of life while
awaiting transplantation. The utility of LVRS will be dependent on
the extent and durability of LVRS improvement; that is, how long
of a delay is worth the morbidity and mortality of LVRS. 
Dr Meyers, what is the algorithm that we should use for choos-
ing LVRS or lung transplantation in patients who are candidates
for both? You have chosen one subset of patients, those with lower
lobe disease or α1-antitrypsin deficiency, as patients who should
proceed straight to transplantation. What is the best procedure for
the 45- to 55-year-old patient who wants to return to work? What
is the best procedure for the 60-year-old patient who is extremely
debilitated? Should we use FEV1 as a guide? You did not show sig-
nificant differences in freedom from transplantation when choos-
ing an FEV1 of less than 25%, but there was a trend. What if one
examined this with an FEV1 of less than 20%? 
Dr Meyers, you and your colleagues have consistently provid-
ed us with outstanding results, first in lung transplantation, and
now with LVRS. The optimum management for these patients will
depend on the summative morbidity and mortality of two sequen-
tial procedures, the differences in 5-year survival, and the extent
and durability of quality of life changes after LVRS or transplan-
tation. The National Emphysema Treatment Trial will provide the
answers for LVRS, and the Transplant Registry data provide most
of the information for transplantation, with a need for a more com-
prehensive examination of quality of life. 
Dr Thomas M. Egan (Chapel Hill, NC). Congratulations on
your results with a difficult operation in a difficult group of
patients. We have not been quite so successful at the University
of North Carolina, where we have done 3 transplants in patients
who have had previous LVRS. The first 2 died, in part as a result
of graft failure that was probably due to a prolonged ischemic
time because of the difficulty encountered in performing pneu-
monectomy in these patients after LVRS. We have seen adhe-
sions that are considerably worse than in the worst cases of cys-
tic fibrosis. The third patient had a double lung transplant, and
although his ischemic times were longer, I think the longer
ischemic time was better tolerated by the double lung recipient
than it was by the 2 single lung recipients who died. 
How many of these patients had single lung versus double
lung transplants, and did the decision to perform double lung
transplantation relate to their previous LVRS and the anticipated
difficulties that one would encounter doing pneumonectomies in
this situation? 
Dr Scott J. Swanson (Boston, Mass). I have another question
along those lines. We have done some transplant operations after
LVRS and have had issues with the phrenic nerve, although we have
not seen any injuries. Do you have any tricks to avoid phrenic nerve
injuries, and did you see any phrenic nerve injuries in this group? 
Dr Stephen Yang (Baltimore, Md). Since you probably have
the most experience, you are aware that there is a certain subpop-
ulation of patients who require LVRS after transplantation. Can
you speculate or do you have any data comparing that group ver-
sus the group that you just presented, regarding either exercise tol-
erance or pulmonary function? 
